The association of the rs1049353 polymorphism of the CNR1 gene with hypoadiponectinemia.

The endocannabinoid system (ECS) is an important physiological system that modulates appetite, food intake, energy homeostasis, substance addiction. It is comprised of the cannabinoid receptors (CB1 and CB2), the endogenous lipid ligands of these receptors and the enzymes that mediate the endogenous ligands' biosynthesis and degradation. CB1 receptor is expressed in the brain, adipose tissue, liver, skeletal muscle, gastrointestinal tract and pancreas. The CB1 receptor is encoded by CNR1 gene located at 6q14-q15 level. The aim of our study was to investigate the possible correlation between rs1049353 polymorphism of the CNR1 gene with levels of adiponectin in a group of subjects from Romania. The study included 305 subjects divided in two groups according to their fasting adiponectin levels. Fasting adiponectin levels were determined using ELISA technique. The genotyping of the rs1049353 polymorphism of the CNR1 gene was made using the Real-Time PCR technique. The statistical analysis was performed using De Finetti's program. The differences between the allelic frequencies indicated that the presence of G-wild allele seems to confer risk for expressing low levels of adiponectin (OR=1.917; 95%C.I.=1.353-2.715; p=0.00023) and A-mutant allele seems to be protective (OR=0.522; 95%C.I.=0.368-0.739; p=0.00023). At the test of allelic positivity, the presence of the G-allele conferred risk of hypoadiponectinemia (OR=2.113; 95%C.I.=1.324-3.373). In conclusion, this study indicates that the rs1049353 polymorphism of the CNR1 gene is associated with decreased levels of adiponectin. Further research is needed in order to elucidate the link between the polymorphisms of the CNR1 gene and adiponectin levels.

[1]  D. D. de Luis,et al.  G1359A polymorphism of the cannabinoid receptor gene (CNR1) and insulin resistance in patients with diabetes mellitus type 2. , 2010, Nutricion hospitalaria.

[2]  T. Noda,et al.  Rimonabant Ameliorates Insulin Resistance via both Adiponectin-dependent and Adiponectin-independent Pathways* , 2009, Journal of Biological Chemistry.

[3]  M. Moța,et al.  The implication of CNR1 gene's polymorphisms in the modulation of endocannabinoid system effects. , 2009, Romanian journal of internal medicine = Revue roumaine de medecine interne.

[4]  F. Salvi,et al.  Renin–angiotensin system, natriuretic peptides, obesity, metabolic syndrome, and hypertension: an integrated view in humans , 2008, Journal of hypertension.

[5]  K. Mackie,et al.  Endocannabinoid system and its implications for obesity and cardiometabolic risk , 2008 .

[6]  W. Hul,et al.  The G1422A variant of the cannabinoid receptor gene (CNR1) is associated with abdominal adiposity in obese men , 2007, Endocrine.

[7]  M. Notarnicola,et al.  Association between cannabinoid type-1 receptor polymorphism and body mass index in a southern Italian population , 2007, International Journal of Obesity.

[8]  T. Meitinger,et al.  No evidence for an involvement of variants in the cannabinoid receptor gene (CNR1) in obesity in German children and adolescents. , 2007, Molecular genetics and metabolism.

[9]  D. Cota,et al.  The emerging role of the endocannabinoid system in endocrine regulation and energy balance. , 2006, Endocrine reviews.

[10]  M. Gonthier,et al.  Presence of the cannabinoid receptors, CB1 and CB2, in human omental and subcutaneous adipocytes , 2006, Histochemistry and Cell Biology.

[11]  S. Woods,et al.  The role of the endocannabinoid system in the regulation of energy homeostasis , 2005 .

[12]  V. Vellani,et al.  Anandamide acts as an intracellular messenger amplifying Ca2+ influx via TRPV1 channels , 2005, The EMBO journal.

[13]  P. Soubrié,et al.  The CB1 receptor antagonist rimonabant reverses the diet‐induced obesity phenotype through the regulation of lipolysis and energy balance , 2005, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[14]  D. Osei-Hyiaman,et al.  Evidence for novel cannabinoid receptors. , 2005, Pharmacology & therapeutics.

[15]  J. Després,et al.  Adiponectinemia in visceral obesity: impact on glucose tolerance and plasma lipoprotein and lipid levels in men. , 2005, The Journal of clinical endocrinology and metabolism.

[16]  G. Kunos,et al.  Atypical cannabinoid stimulates endothelial cell migration via a Gi/Go-coupled receptor distinct from CB1, CB2 or EDG-1. , 2004, European journal of pharmacology.

[17]  P. Soubrié,et al.  CB1 cannabinoid receptor knockout in mice leads to leanness, resistance to diet-induced obesity and enhanced leptin sensitivity , 2004, International Journal of Obesity.

[18]  C. Flachskamm,et al.  The endogenous cannabinoid system affects energy balance via central orexigenic drive and peripheral lipogenesis. , 2003, The Journal of clinical investigation.

[19]  P. Soubrié,et al.  The cannabinoid CB1 receptor antagonist SR141716 increases Acrp30 mRNA expression in adipose tissue of obese fa/fa rats and in cultured adipocyte cells. , 2003, Molecular pharmacology.

[20]  B. Lutz Molecular biology of cannabinoid receptors. , 2002, Prostaglandins, leukotrienes, and essential fatty acids.

[21]  M. Lazdunski,et al.  The endocannabinoid anandamide is a direct and selective blocker of the background K+ channel TASK‐1 , 2001, The EMBO journal.

[22]  P. Sasieni From genotypes to genes: doubling the sample size. , 1997, Biometrics.

[23]  M. Herkenham,et al.  Cannabinoid receptor localization in brain. , 1990, Proceedings of the National Academy of Sciences of the United States of America.